After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
In the 1920s, Indianapolis was one of the most innovative cities in the nation. But after “the dark tragedy of the roaring twenties,” Indianapolis lost its edginess for decades and only recently has begun to regain it.
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
Puerto Rico officials are looking to replace an expiring tax with a new levy to draw much-needed revenue from the world's best-selling medications while seeking to avoid driving U.S. manufacturers such as Eli Lilly and Co. from the commonwealth.
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.